OECD BNCT

Project on Open and Responsible Innovation for Health (OECD BNCT)

Current and imminent advances in science and technology allow new forms of targeted intervention in the basic processes of human biology -- including ageing, reproduction, cellular repair, immunity, and neurological function. There is a strong imperative to translate such discoveries into diagnostics and therapies that address grand health challenges -- such as Alzheimer’s disease and other neurodegenerative disorders, cancer, infectious diseases -- but substantial challenges remain in terms of constructing the right economic, ethical and social context for innovation and access. One set of policy challenges has to do with balancing the imperatives of open innovation, commercialisation, and access. How to ensure that advanced therapies will develop in a socially responsible and sustainable manner?

Contact: hermann[dot]garden[at sign]oecd[dot]org 

Expert Meeting

Gene editing for advanced therapies: governance, policy, and society

The 1.5-day expert meeting "Gene editing for advanced therapies: governance, policy, and society" will discuss governance mechanisms for the responsible use of gene editing technologies in somatic cells to promote human health.

6-7 July 2017, BMBF, Berlin, Germany. Draft agenda: link

 

The purpose of the expert meeting is to explore the core scientific, legal, regulatory and societal challenges facing the responsible development and use of gene editing for advanced therapies, such as regenerative medicine and cell therapy. International stakeholders will aim to identify where new forms of collaboration across science and society may help to promote a reasonable balance of risk and benefit in personalised health and well-being. 

Objectives:

  1. Pool ideas and approaches from countries for the responsible development of gene editing technologies in advanced and personalised therapies, especially in relation to research policy, ethical, legal and social aspects, regulation and governance, and innovation policy.
  2. Examine options available to social actors in, and around, public engagement approaches designed to inform governance and regulation.  
  3. Draw more general policy lessons for the responsible development of emerging technologies. 

 

  

 

 

Disclaimer: Any opinions, findings, and conclusions or recommendations expressed in  this material are those of the author(s) and do not necessarily reflect the views of the KLRI.

Lausanne Dialogue

Delivering Next Generation Alzheimer's Treatments:

Connecting Research, Regulation and Access

27-28 October 2016, Lausanne, Switzerland

 

Stopping Alzheimer's disease by 2025 requires investment, collaboration, and creativity. That is why at the 3rd Lausanne Dialogue 27-28 October 2016 we will take an interdisciplinary approach to discuss the following themes with regulators, researchers, industry representatives, payers, and those living with dementia:  

  • What are the key challenges facing the regulatory environment from now until 2025 and how can we resolve them?
  • How can the evidence be developed to support the payer community?
  • What can we learn from other diseases - and how can we apply these learnings to Alzheimer's? 

The OECD Working Party on BNCT is at the forefront to advise on how research and innovation in biotechnology, nanotechnology and novel, emerging and converging technologies can contribute to address global challenge of Alzheimer’s disease and other dementias. The Lausanne Dialogue will help keep the momentum of ongoing, global stakeholder action, for example: the UK G8 ‘Dementia Summit’ (2013); OECD work on collaborative research and data sharing; the first Lausanne workshop ‘Enhancing translational research and clinical development for Alzheimer’s disease and other dementias: The way forward’ (2014); and the ‘Ministerial Conference on Global Action Against Dementia’ (2015), organised by the WHO with support from the Department of Health of UK and the OECD. Further details on OECD work on dementia click here.

The Lausanne Dialogue is organised under the auspices of the OECD Working Party on Biotechnology, Nanotechnology, and Converging Technologies (BNCT). It is being hosted by the Government of Switzerland and supported by the Global CEO Initiative on Alzheimer’s Disease and Alzheimer’s Disease International (ADI). Link: Draft Agenda

   

Report a Problem

If you have problems logging into this webpage, and you are a registered delegate of the OECD Working Party on Biotechnology, Nanotechnology and Converging Technologies (BNCT), or a registered member of a BNCT Task Force, who requires access to the private section of this webpage, please CLICK HERE to report your problem.

Project Flyer

Past Events

  • Proceedings of a Workshop, NAS (USA): International Perspectives on Integrating Ethical, Legal, and Social Considerations into the Development of Non-Invasive Neuromodulation Devices; Washington D.C., 15 September 2016
  • NERF Neurotechnology Symposium, Leuven, Belgium, 2-3 May 2016 (OECD presentation)
  • Lausanne II Workshop: 15-16 December 2015, Lausanne, Switzerland (Workshop Report)
  • STI Seminar: 'Converging Technologies and Advanced Manufacturing', Mihail Roco, Paris, 2 December 2015
  • Lausanne I Workshop: 10-11 November 2014, Lausanne, Switzerland (Workshop Report)